Adverse drug reactions & drug interactions in MDR-TB patients

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Medicine

Background:

• Tuberculosis (TB) treatment, particularly for drug-resistant TB (DR-TB), involves multiple drugs over extended periods.
• These anti-TB drugs can lead to adverse drug reactions (ADRs), with DR-TB regimens posing a higher risk.
• Patients with comorbidities may experience drug interactions, necessitating dose adjustments or drug changes.

Purpose of the Study:

• To outline common ADRs associated with anti-TB drugs used in DR-TB management.
• To detail frequent drug interactions involving anti-TB medications.
• To provide practical recommendations for identifying causative agents and managing ADRs and interactions.

Main Methods:

• Review of literature on ADRs and drug interactions of anti-TB drugs.
• Analysis of clinical scenarios involving DR-TB patients.
• Development of management strategies based on identified risks.

Main Results:

• Most ADRs from DR-TB drugs are mild to moderate and manageable with supervision.
• Severe or life-threatening ADRs may necessitate drug discontinuation.
• Drug interactions are common in TB patients with comorbidities, requiring careful management.

Conclusions:

• Effective management of ADRs and drug interactions is crucial for patient compliance and successful TB treatment.
• Clinicians require guidance on identifying and managing potential adverse events and interactions in DR-TB patients.
• Proactive monitoring and intervention are key to mitigating risks associated with DR-TB therapy.